| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Medical Research Laboratories, Institute of Experimental Clinical Research, Aarhus University (C.S., J.F., H.Ø., N.M., A.F.), and the Surgical Research Unit, Department of Surgery L, University Hospital of Aarhus (P.K.-N., M.B.J., S.L.), DK-8000 Aarhus C, Denmark
Address all correspondence and requests for reprints to: Dr. Christian Skjærbæk, Medical Research Laboratories, Aarhus Kommune Hospital, Building 3, DK-8000 Aarhus C, Denmark. E-mail: cs{at}afdm.aau.dk
Major surgery is accompanied by extensive proteolysis of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3). Proteolysis of IGFBP-3 is generally believed to increase IGF bioavailability due to a diminished affinity of the IGFBP-3 fragments for IGFs. We have investigated 18 patients undergoing elective ileo-anal J-pouch surgery. Patients were randomized to treatment with GH (12 IU/day; n = 9) or placebo (n = 9) from 2 days before to 7 days after operation. Free IGF-I and IGF-II were measured by ultrafiltration of serum, and IGFBP-3 proteolytic activity was determined by a [125I]recombinant human IGFBP-3 degradation assay. In the GH-treated group, total IGF-I increased preoperatively by 99%. Postoperatively, total IGF-I decreased by 48% (placebo) and 52% (GH). Immunoassayable IGFBP-3 decreased by 27% (placebo) and 26% (GH). In the placebo-treated group, free IGF-I was unchanged throughout the study. In the GH-treated group, free IGF-I increased by 277% preoperatively and remained elevated after operation. IGFBP-3 proteolytic activity increased by 6373% after operation. The relative elevations of free IGF-I levels despite decreased total IGF-I levels could thus relate to augmented IGFBP-3 proteolysis.
This article has been cited by other articles:
![]() |
L. Moller, H. Norrelund, N. Jessen, A. Flyvbjerg, S. B. Pedersen, B. D. Gaylinn, J. Liu, M. O. Thorner, N. Moller, and J. O. Lunde Jorgensen Impact of Growth Hormone Receptor Blockade on Substrate Metabolism during Fasting in Healthy Subjects J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4524 - 4532. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Clemmons, M. Sleevi, and W. H. Busby Jr. Recombinant, Nonglycosylated Human Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) Is Degraded Preferentially after Administration to Type II Diabetics, Resulting in Increased Endogenous Glycosylated IGFBP-3 J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6561 - 6568. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Norrelund, J. Frystyk, J. O. L. Jorgensen, N. Moller, J. S. Christiansen, H. Orskov, and A. Flyvbjerg The Effect of Growth Hormone on the Insulin-Like Growth Factor System during Fasting J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3292 - 3298. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Nygren, C. Carlsson-Skwirut, K. Brismar, A. Thorell, O. Ljungqvist, and P. Bang Insulin infusion increases levels of free IGF-I and IGFBP-3 proteolytic activity in patients after surgery Am J Physiol Endocrinol Metab, October 1, 2001; 281(4): E736 - E741. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dall, K. H. W. Lange, M. Kjær, J. O. L. Jørgensen, J. S. Christiansen, H. Ørskov, and A. Flyvbjerg No Evidence of Insulin-Like Growth Factor-Binding Protein 3 Proteolysis during a Maximal Exercise Test in Elite Athletes J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 669 - 674. [Abstract] [Full Text] |
||||
![]() |
S. Kalmijn, J. A. M. J. L. Janssen, H. A. P. Pols, S. W. J. Lamberts, and M. M. B. Breteler A Prospective Study on Circulating Insulin-Like Growth Factor I (IGF-I), IGF-Binding Proteins, and Cognitive Function in the Elderly J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4551 - 4555. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |